Board of Directors
The following members make up the BioPharmX Board of Directors.
Michael Hubbard served as a senior audit partner at Deloitte & Touche LLP from August 2007 until retiring in June 2014 and also at PricewaterhouseCoopers LLP from September 1986 to July 2007. In these roles, he served private and publicly held clients across the life sciences, waste management, construction, and technology sectors, advising domestic and international issuer companies on complex transactions, including 19 IPOs and numerous follow on equity and debt offerings. Mr. Hubbard holds a B.A. degree in Business Administration with a concentration in Accounting and an MBA degree from Washington State University. He is a licensed CPA in the states of Washington and California and is a certified practitioner of international financial reporting standards.
A Silicon Valley veteran, Ms. Krammer has deep experience guiding healthcare and other enterprises to identify and fulfill unmet consumer needs. She has overseen commercial operations at diverse companies, such as aesthetic market leader Reliant Technologies, biomedical engineer Medtronic, print imaging manufacturer Tektronix and telecommunications giant AT&T. She has also counseled companies, such as American Express, GSK, Medicis Pharmaceuticals and Weight Watchers NA. Krammer graduated from the University of South Carolina and completed post-graduate studies at Webster University and the University of Paris – Sorbonne.
An experienced entrepreneurial pharmaceutical and med-tech C-level executive, Dr. Tierney has an extensive track record of delivering success. He has overseen the growth and successful exit of a number of specialty pharmaceutical and medical device companies. Most recently, Dr. Tierney served as president and chief executive officer of Icon Bioscience, leading his team to FDA approval of its New Drug Application (NDA) for DEXYCU; in 2018. Dr. Tierney was president and chief operating officer of Oceana Therapeutics, a specialty therapeutic company he co-founded in 2008 and was later acquired by Salix Pharmaceuticals. In his role as president and chief executive officer of Valera Pharmaceuticals, Tierney raised over $65 million in funding and completed a successful IPO and oversaw NDA approvals of VANTAS and SUPPRELIN LA. In addition to Dr. Tierney's leadership roles, he has extensive experience in raising capital and has held a position with investment firm, Signet Health Partners. He is the recipient of two Ernst & Young Entrepreneur of the Year awards. Dr. Tierney also serves on the board of directors of Catalyst Pharmaceuticals, Kempharm, Bimeda, and Palvella Therapeutics. Dr. Tierney received his medical degree from The Royal College of Surgeons in Dublin, Ireland.
Stephen Morlock served as executive vice president and chief financial officer at Otis Spunkmeyer, Inc. from May 1994 until his retirement in June 2004. He also served as controller from August 1992 to April 1994. Prior to that, he held various management positions in accounting, financial planning, and internal audit at Westinghouse Electric Supply Company from November 1977 to July 1992. Since his retirement in June 2004, Mr. Morlock has not been active in any business activities. Mr. Morlock holds a B.S. degree in Accounting from San Diego State University.
Dr. R. Todd Plott is an experienced developer of prescription pharmaceutical drugs who has helped small and large companies create their own products. He has been involved in nine different development programs that have received approval by the U.S. Food and Drug Administration (FDA) and other international regulatory agencies. He personally led and supervised five of these programs from initiation through approval. Establishing and leading teams of experts focused on New Drug Application (NDA) approval has been Dr. Plott’s strength. During his 15 years in the industry, he has built the development and regulatory departments of companies from ground up, hiring experts in formulation, preclinical, clinical, and regulatory affairs to form departments that produced results. One of his best-known contributions to dermatology and most challenging engagement was the development of an extended-release minocycline for the treatment of acne vulgaris, SOLODYN™, the first oral antibiotic designed and approved by the FDA for the treatment of acne vulgaris.